W e have come a long way since the identification of the first human tumor antigen
recognized by autologous CTL. This report provides a brief appraisal of these antigens and …

The adoptive transfer of tumor‐infiltrating lymphocytes (TH.) along with interleukin (H.)‐2 into
autologous patients with cancer resulted in the objective regression of tumor, indicating that …

Cell-based antitumor immunity is driven by CD8+ cytotoxic T cells bearing TCR that
recognize specific tumor-associated peptides bound to class I MHC molecules. Of several …

Immunogenic peptides of human tumor Ag have been used to generate antigen-specific
CTL. However, the vast majority of these peptide-specific CTL clones are of low avidity and …

The ability of tumor-reactive T cells to mediate in vivo tumor regression has been
demonstrated in murine tumor models and by the clinical responses to adoptive …

The molecular characterization of T-cell-defined tumor-associated antigens has provided
targets for cell-mediated immunotherapy for malignant diseases. The success of this strategy …

Because of tolerance mechanisms, it has been hard to identify the T cell receptors (TCRs) of
high-avidity T cells against self (for example, tumor) antigens. TCRs that are specific for …

Recent progress in the structural identification of human melanoma antigens recognized by
autologous cytotoxic T cells has led to the recognition of a new melanocyte differentiation …

Recognition of self is emerging as a theme for the immune recognition of human cancer.
One question is whether the immune system can actively respond to normal tissue …

Recent deep sequencing studies on T-cell receptor (TCR) repertoire have provided robust
data to characterize diversity of T-cell immune responsiveness to a wide variety of peptide …